SCHEMBL2807423

SCHEMBL2807423

CC(=O)OCc1nc2cnc3ccccc3c2s1

nearest known ligand 0.61

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 2/20 0.61
CYP2C19 P33261 2/20 0.61
L3MBTL1 Q9Y468 3/20 0.43
MAPT P10636 4/20 0.41
RAB9A P51151 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
TSHR P16473 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2C9 P11712 1/20 0.39
HPGD P15428 1/20 0.39
LMNA P02545 1/20 0.39
ALDH1A1 P00352 4/20 0.39
KDM4E B2RXH2 2/20 0.39
RECQL P46063 1/20 0.39
KMT2A Q03164 1/20 0.39
NPC1 O15118 2/20 0.38
HTT P42858 1/20 0.38
TOP2A P11388 1/20 0.37
TOP2B Q02880 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4965121 0.83 CYP1A2 (0.47) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL1528140 0.82 SMN1; SMN2 (0.43) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL2809228 0.81 NPC1 (0.41) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL1528127 0.80 TLR8 (0.41) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL4970650 0.80 KMT2A (0.40) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL13128110 0.80 NPC1 (0.40) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL2806860 0.78 TLR8 (0.37) CYP1A2CYP2C19L3MBTL1MAPTRAB9A
SCHEMBL1527945 0.78 TLR8 (0.56) MAPTRAB9AKDM4ENPC1
SCHEMBL2810620 0.78 TLR8 (0.64) CYP1A2CYP2C19ALDH1A1
SCHEMBL2814274 0.77 CYP1A2 (0.54) CYP1A2CYP2C19L3MBTL1MAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8378102-B2 Oxime and hydroxylamine substituted thiazolo[4,5-c] ring compounds and methods 3M INNOVATIVE PROPERTIES COMPANY (US) 2013-02-19 US disclosed
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods COLEY PHARMACEUTICAL GROUP, INC (US) 2010-09-23 US disclosed
EP-1877056-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLOÝ4,5-C¨RING COMPOUNDS AND METHODS Coley Pharmaceutical Group, Inc. (US) 2008-01-16 EP disclosed
WO-2007120121-A2 OXIME AND HYDROXYLAMINE SUBSTITUTED THIAZOLO[4,5-C] RING COMPOUNDS AND METHODS COLEY PHARMACEUTICAL GROUP, INC. (US) 2007-10-25 WO disclosed
US-7148232-B2 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY (US) 2006-12-12 US disclosed
EP-1380587-B1 Oxazolo, thiazolo and selenazolo [4,5-c]naphthyridine-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES CO (US) 2006-03-15 EP disclosed
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2005-02-03 US disclosed
US-6809203-B2 IMMUNOMODULATORS; INDUCING CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON-ALPHA AND/OR TUMOR NECROSIS FACTOR-ALPHA 3M INNOVATIVE PROPERTIES COMPANY 2004-10-26 US disclosed
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2004-06-24 US disclosed
US-6703402-B2 IMMUNOMODULATORS; INDUCERS OF CYTOKINE BIOSYNTHESIS INCLUDING INTERFERON AND/OR TUMOR NECROSIS FACTOR; ANTITUMOR AGENTS, VIRICIDES 3M INNOVATIVE PROPERTIES COMPANY 2004-03-09 US disclosed
EP-1100802-B1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLINE-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES CO (US) 2003-09-24 EP disclosed
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-04-03 US disclosed
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2003-03-06 US disclosed
US-6440992-B1 ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; USEFUL FOR THERAPY OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY 2002-08-27 US disclosed
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof 3M INNOVATIVE PROPERTIES COMPANY 2002-06-13 US disclosed
US-6323200-B1 THE COMPOUNDS ARE IMMUNOMODULATORS AND INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR, AND INHIBIT THE T-HELPER-TYPE 2 IMMUNE RESPONSE. 3M INNOVATIVE PROPERTIES COMPANY 2001-11-27 US disclosed
EP-1100802-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M Innovative Properties Company (US) 2001-05-23 EP disclosed
US-6110929-A IMMUNOMODULATORS WHICH INDUCE CYTOKINE BIOSYNTHESIS, INCLUDING INTERFERON AND/OR TUMOR BIOSYNTHESIS, NECROSIS FACTOR AND INHIBIT T-HELPER-TYPE 2 IMMUNE RESPONSE; FOR TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-08-29 US disclosed
WO-2000006577-A1 OXAZOLO, THIAZOLO AND SELENAZOLO [4,5-c]-QUINOLIN-4-AMINES AND ANALOGS THEREOF 3M INNOVATIVE PROPERTIES COMPANY (US) 2000-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064968-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 CYP1A2 1066/4885CYP2C19 2140/4885L3MBTL1 3333/4885
US-20020072528-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 CYP1A2 1066/4885CYP2C19 2140/4885L3MBTL1 3333/4885
US-20030065006-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 CYP1A2 1066/4885CYP2C19 2140/4885L3MBTL1 3333/4885
US-20050026943-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, IL2, IRF3 CYP1A2 730/4885CYP2C19 1889/4885L3MBTL1 3504/4885
US-20040122041-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 CYP1A2 1066/4885CYP2C19 2140/4885L3MBTL1 3333/4885
US-20030045545-A1 Oxazolo, thiazolo and selenazolo [4,5-c]-quinolin-4-amines and analogs thereof IFNG, THPO, IL2 CYP1A2 1066/4885CYP2C19 2140/4885L3MBTL1 3333/4885
US-20100240693-A1 Oxime and Hydroxylamine Substituted Thiazolo [4,5-C] Ring Compounds and Methods IL4, IL2, TH CYP1A2 352/4885CYP2C19 491/4885L3MBTL1 3690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.